Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| Genmab Achieves $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen | 25 Oct 2015 |
| Major Shareholder Announcement | 23 Oct 2015 |
| Genmab’s Financial Calendar for 2016 | 22 Oct 2015 |
| Articles of Association for Genmab A/S | 20 Oct 2015 |
| Major Shareholder Announcement | 16 Oct 2015 |